Bioventus (BVS) Competitors

Envista (NYSE:NVST) and Bioventus (NYSE:BVS) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings, community ranking, media sentiment and profitability.

Does the media prefer NVST or BVS?

In the previous week, Bioventus had 3 more articles in the media than Envista. MarketBeat recorded 8 mentions for Bioventus and 5 mentions for Envista. Envista's average media sentiment score of 1.64 beat Bioventus' score of 1.29 indicating that Envista is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Envista	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Bioventus	7 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has higher earnings & valuation, NVST or BVS?

Bioventus has lower revenue, but higher earnings than Envista. Bioventus is trading at a lower price-to-earnings ratio than Envista, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Envista	$2.51B	1.16	-$1.12B	-$6.49	-2.61
Bioventus	$573.28M	1.29	-$156.23M	-$0.51	-17.71

Which has more risk & volatility, NVST or BVS?

Envista has a beta of 1.33, indicating that its share price is 33% more volatile than the S&P 500. Comparatively, Bioventus has a beta of 0.86, indicating that its share price is 14% less volatile than the S&P 500.

Is NVST or BVS more profitable?

Bioventus has a net margin of -7.11% compared to Envista's net margin of -44.56%. Bioventus' return on equity of 15.61% beat Envista's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Envista	-44.56%	3.86%	2.21%
Bioventus	-7.11%	15.61%	4.01%

Do analysts recommend NVST or BVS?

Envista presently has a consensus target price of $20.18, indicating a potential upside of 18.95%. Bioventus has a consensus target price of $15.00, indicating a potential upside of 66.11%. Given Bioventus' stronger consensus rating and higher probable upside, analysts clearly believe Bioventus is more favorable than Envista.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Envista	2 Sell rating(s)	10 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.07
Bioventus	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

Do insiders and institutionals have more ownership in NVST or BVS?

62.9% of Bioventus shares are held by institutional investors. 1.3% of Envista shares are held by company insiders. Comparatively, 32.9% of Bioventus shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Does the MarketBeat Community favor NVST or BVS?

Envista received 3 more outperform votes than Bioventus when rated by MarketBeat users. However, 63.27% of users gave Bioventus an outperform vote while only 33.33% of users gave Envista an outperform vote.

Company	Underperform	Outperform
Envista	Outperform Votes 34 33.33%	Underperform Votes 68 66.67%
Bioventus	Outperform Votes 31 63.27%	Underperform Votes 18 36.73%

Summary

Bioventus beats Envista on 12 of the 18 factors compared between the two stocks.